Menu
2023 was a year marked by significant advancements, strengthening collaborations, and expanding our research impact on a global scale as TROG continued to lead and support impactful clinical trials. Research highlights, patient stories, TROG Cancer Research Central Operations Office and committee updates along with membership growth and finance reporting are some of the highlights of the 2023 Annual Research Report.
Some of this year's highlights include: A successful virtual ASM; Continued trial activity with two trials reaching accrual, 12 new clinical trial proposals submitted, and 124 participants recruited; New investigator-initiated trials developed collaboratively with other Cancer Collaborative Trials Groups; Implementing new processes for financial reporting enabling more detailed and timely reporting to the Board; and finally, Submission of Cancer Australia ‘Support for Cancer Clinical Trials Program Grant’.
Some of this year's highlights include: A successful virtual ASM; Continued trial activity with two trials reaching accrual, 12 new clinical trial proposals submitted, and 124 participants recruited; New investigator-initiated trials developed collaboratively with other Cancer Collaborative Trials Groups; Implementing new processes for financial reporting enabling more detailed and timely reporting to the Board; and finally, Submission of Cancer Australia ‘Support for Cancer Clinical Trials Program Grant’.
The past year has been another busy period
for TROG Cancer Research with many new
initiatives at all levels already showing positive
results.
The emergence of the COVID-19 pandemic in early
2020 posed new challenges for the TROG Central
Operations Office (TCOO) and the Board. Due to the
rapidly changing situation and the need for the Board
to manage associated risks, the Board convened
and scheduled several virtual meetings during each
quarter.
Over three decades, TROG Cancer Research has facilitated hundreds of clinical trials that have helped improve the outcome and quality of life for more than 14,500 cancer patients globally.
Over that time, the prognosis of cancer patients has improved considerably. In the 1980s the cancer survival rate was less than 50 per cent. Today, for some cancers, the survival rate is as high as 90 per cent.
The research undertaken by TROG Cancer Research members continues to provide evidence for the efficacy of new and improved radiation therapy treatments for patients; producing clinically relevant results that are incorporated into practice and policy.
Membership continues to grow, and the contribution of our membership is exceptional. The time and expertise provided by our members make TROG Cancer Research the organisation it is today.
We now also act as a Contract Research Organisation for non-TROG Cancer Research trials.
We continue to conduct robust research and engage through collaboration across Australia and the world, as a research leader.
Financial sustainability has been identified as the number one pillar to ensure our organisation will continue our core business of radiation therapy clinical trials.
TROG Cancer Research has continued to cultivate its reputation as a world-class research organisation and an industry leader.
To enhance our public profile, a television advertisement was launched in 2015 and has received airplay as a community service announcement to promote our research and appeal to the community for donations.
In the past year, TROG Cancer Research has Our constant aim is to improve the lives of those affected by cancer through innovative research and treatment techniques, as we strive towards breakthrough discoveries.
We are proud to be known as the highest recruiting collaborative cancer trials group in Australia.
If you have any questions regarding these reports, please contact the TROG Central Office on +61 02 401 43911 or email us by clicking the link below.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292